UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 10-Q
[X] QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30,
2010
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT
OF 1934
Commission file number 000-53665
MEDICAL CARE TECHNOLOGIES
INC.
(Exact name of registrant as specified in its
charter)
NEVADA
(State or other jurisdiction of
incorporation or organization)
Room 815, No. 2 Building Beixiaojie, Dongzhimen Nei
Beijing, Peoples Republic of China 10009
(Address of
principal executive offices, including zip code.)
(8610) 6407 0580
(Registrants telephone
number, including area code)
Check whether the issuer (1) filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the last 90 days.
YES [X] NO [ ]
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files)
YES [ ] NO [ ]
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer, accelerated
filer, non-accelerated filer, and smaller reporting company in Rule 12b-2
of the Exchange Act.
Large accelerated Filer
[ ]
|
Accelerated Filer
[ ]
|
Non-accelerated Filer
[ ]
|
Smaller Reporting Company
[X]
|
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).
YES [ ] NO [X]
State the number of shares outstanding of each of the issuers
classes of common equity, as of the latest practicable date: 99,400,000 as of
August 13, 2010.
-1-
TABLE OF CONTENTS
- 2 -
ITEM 1.
|
FINANCIAL STATEMENTS.
|
Medical Care Technologies Inc.
|
(A Development Stage Company)
|
June 30, 2010
|
Medical Care Technologies Inc.
|
(A Development Stage Company)
|
Consolidated Balance Sheets
|
(unaudited)
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
1,185
|
|
$
|
475
|
|
Prepaid expenses
|
|
45,500
|
|
|
|
|
Total Current Assets
|
|
46,685
|
|
|
475
|
|
Property and equipment, net of accumulated depreciation of
$20,000
|
|
30,000
|
|
|
|
|
Intangible assets, net of accumulated amortization of $210,564
|
|
210,564
|
|
|
|
|
Total Assets
|
$
|
287,249
|
|
$
|
475
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
(DEFICIT )
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
Accounts payable
|
$
|
56,510
|
|
$
|
31,202
|
|
Due to related parties
|
|
35,005
|
|
|
25,439
|
|
Accrued liabilities
|
|
4,923
|
|
|
|
|
Loans
payable
|
|
80,717
|
|
|
14,000
|
|
Total Current Liabilities
|
|
177,155
|
|
|
70,641
|
|
Loans
payable
|
|
|
|
|
56,740
|
|
Total Liabilities
|
|
177,155
|
|
|
127,381
|
|
Stockholders Equity (Deficit)
|
|
|
|
|
|
|
Preferred Stock, 100,000,000 shares
authorized, $0.00001 par value,
No shares issued and outstanding as of
June 30, 2010 and December 31, 2009
|
|
|
|
|
|
|
Common Stock, 150,000,000 shares authorized, $0.00001 par
value,
99,400,000 and 98,900,000 shares issued and outstanding as of
June 30, 2010 and December 31, 2009, respectively
|
|
994
|
|
|
989
|
|
Additional Paid-in Capital
|
|
621,634
|
|
|
50,511
|
|
Deficit
Accumulated During the Development Stage
|
|
(512,534
|
)
|
|
(178,406
|
)
|
Total Stockholders Equity (Deficit)
|
|
110,094
|
|
|
(126,906
|
)
|
Total Liabilities
and Stockholders Equity (Deficit)
|
$
|
287,249
|
|
$
|
475
|
|
(The accompanying notes are an integral part of these unaudited
consolidated financial statements)
F-1
Medical Care Technologies Inc.
|
(A Development Stage Company)
|
Consolidated Statements of Expenses
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
February 27, 2007
|
|
|
|
For the three months ended
|
|
|
For the six months ended
|
|
|
(Inception)
|
|
|
|
June 30,
|
|
|
June 30,
|
|
|
To June 30,
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
$
|
38,077
|
|
$
|
16,187
|
|
$
|
73,689
|
|
$
|
31,002
|
|
$
|
148,330
|
|
Depreciation and amortization expense
|
|
115,282
|
|
|
|
|
|
230,564
|
|
|
|
|
|
230,564
|
|
Management fees
|
|
15,000
|
|
|
9,000
|
|
|
30,000
|
|
|
9,000
|
|
|
45,692
|
|
Total Expenses
|
|
(168,359
|
)
|
|
(25,187
|
)
|
|
(334,253
|
)
|
|
(40,002
|
)
|
|
(424,586
|
)
|
Foreign currency
exchange gain (loss)
|
|
362
|
|
|
|
|
|
125
|
|
|
72
|
|
|
(638
|
)
|
Loss Before Discontinued Operations
|
|
(167,997
|
)
|
|
(25,187
|
)
|
|
(334,128
|
)
|
|
(39,930
|
)
|
|
(425,224
|
)
|
Loss from Discontinued Operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(87,310
|
)
|
Net Loss
|
$
|
(167,997
|
)
|
$
|
(25,187
|
)
|
$
|
(334,128
|
)
|
$
|
(39,930
|
)
|
$
|
( 512,534
|
)
|
Net Loss Per Common Share Basic and Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued Operations
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
|
|
Continued Operations
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
|
|
|
Net
Loss
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
Common Shares Outstanding Basic and Diluted
|
|
99,400,000
|
|
|
41,400,000
|
|
|
99,312,000
|
|
|
58,237,000
|
|
|
|
|
(The accompanying notes are an integral part of these unaudited
consolidated financial statements)
F-2
Medical Care Technologies Inc.
|
(A Development Stage Company)
|
Consolidated Statements of Cash Flows
|
(unaudited)
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
February 27, 2007
|
|
|
|
Six months ended
|
|
|
(Date of Inception)
|
|
|
|
June 30,
|
|
|
To June 30,
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period
|
$
|
(334,128
|
)
|
$
|
(39,930
|
)
|
$
|
(512,534
|
)
|
|
|
|
|
|
|
|
|
|
|
Adjustment to reconcile net
loss to cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
Donated services and expenses
|
|
|
|
|
|
|
|
10,500
|
|
Depreciation and amortization
|
|
230,564
|
|
|
|
|
|
230,564
|
|
|
|
|
|
|
|
|
|
|
|
Changes in operating assets
and liabilities:
|
|
|
|
|
|
|
|
|
|
Prepaid expenses
|
|
(45,500
|
)
|
|
(2,000
|
)
|
|
(45,500
|
)
|
Accounts payable
|
|
25,308
|
|
|
28,912
|
|
|
56,510
|
|
Accrued liabilities
|
|
4,923
|
|
|
1,420
|
|
|
4,923
|
|
Net Cash Used in Operating Activities
|
|
(118,833
|
)
|
|
(11,598
|
)
|
|
(255,537
|
)
|
|
|
|
|
|
|
|
|
|
|
Financing Activities
|
|
|
|
|
|
|
|
|
|
Issuance of common stock for cash
|
|
100,000
|
|
|
|
|
|
141,000
|
|
Proceeds from Loans Payable
|
|
9,977
|
|
|
|
|
|
80,717
|
|
Due
to related party
|
|
9,566
|
|
|
1,994
|
|
|
35,005
|
|
Net Cash Provided by Financing Activities
|
|
119,543
|
|
|
1,994
|
|
|
256,722
|
|
|
|
|
|
|
|
|
|
|
|
Increase (Decrease) in Cash
and Cash Equivalent
|
|
710
|
|
|
(9,604
|
)
|
|
1,185
|
|
|
|
|
|
|
|
|
|
|
|
Cash Beginning of Period
|
|
475
|
|
|
9,791
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash End of Period
|
$
|
1,185
|
|
$
|
187
|
|
$
|
1,185
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures
|
|
|
|
|
|
|
|
|
|
Interest paid
|
|
|
|
|
|
|
|
|
|
Income taxes paid
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Cash Disclosures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reclass of related party debt to accounts
payable
|
$
|
23,445
|
|
$
|
|
|
$
|
46,255
|
|
Repurchase of common stock
|
$
|
|
|
$
|
15,000
|
|
$
|
15,000
|
|
Shares issued for acquisition of assets
|
$
|
471,128
|
|
$
|
|
|
$
|
471,128
|
|
Reclassification from long term to short term debt
|
$
|
56,740
|
|
$
|
|
|
$
|
56,740
|
|
(The accompanying notes are an integral part of these unaudited
consolidated financial statements)
F-3
Medical Care Technologies Inc.
|
(A Development Stage Company)
|
Notes to the Consolidated Financial Statements
|
(unaudited)
|
1.)
|
Development Stage Company and Going Concern
|
Medical Care Technologies Inc. (the
Company) was incorporated in the State of Nevada on February 27, 2007 under
the name of Aventerra Explorations Inc and changed its name from Aventerra
Exploration Inc to AM Oil Resources & Technology Inc. on December 3,
2008. On September 28, 2009, the Company incorporated Medical Care Technologies
Inc. for the sole purpose of effecting a name change. On October 6, 2009, the
Company effected a merger with the wholly owned subsidiary and assumed the
subsidiarys name. In conjunction with the name change, the Company has also
been granted a new trading symbol of MDCE. The Company is in the development
stage as defined by Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) 915,
Development Stage Entities
.
During the six months ended June 30,
2010, the Company issued 57.3 million shares of common stock in connection with
the acquisition of certain software and computer equipment. The shares
represented 57.6% of the total issued and outstanding shares of the Company,
resulting in a change in control. This change of control will limit the
utilization of our NOL carryforwards in future tax periods.
Going Concern
These consolidated financial statements
have been prepared on a going concern basis, which implies the Company will
continue to realize its assets and discharge its liabilities in the normal
course of business. The Company has not generated revenues since inception and
has never paid any dividends and is unlikely to pay dividends or generate
earnings in the immediate or foreseeable future. The continuation of the Company
as a going concern is dependent upon the continued financial support from its
shareholders, the ability of the Company to obtain necessary equity financing to
continue operations and to determine the existence, discovery and successful
exploitation of economically recoverable reserves in its resource properties,
confirmation of the Companys interests in the underlying properties, and the
attainment of profitable operations. As at June 30, 2010, the Company has a
working capital deficit and has accumulated losses since inception. These
consolidated financial statements do not include any adjustments to the
recoverability and classification of recorded asset amounts and classification
of liabilities that might be necessary should the Company be unable to continue
as a going concern. These factors raise substantial doubt regarding the
Companys ability to continue as a going concern.
Consolidation
These consolidated financial statements
and related notes are presented in accordance with accounting principles
generally accepted in the United States, and are expressed in US dollars. These
consolidated financial statements include the accounts of the Company and its
wholly owned subsidiary, Aventerra Explorations Ltd, a company incorporated in
England. All inter-company accounts and transactions have been eliminated.
Reclassification
Certain prior year amounts have been
reclassified to conform with the current year presentation.
Recently Adopted Accounting
Pronouncements
The Company has implemented all new
accounting pronouncements that are in effect and that may impact its financial
statements and does not believe that there are any other new accounting
pronouncements that have been issued that might have a material impact on its
financial position or results of operations.
2.
|
Asset Acquisition Agreement
|
|
|
|
On January 9, 2010, the Company entered into an Asset
Acquisition Agreement to acquire various computers, software, and
technologies (the assets) held by Great Union Corporation (Great
Union), a Hong Kong corporation. In consideration, the Company agreed to
issue 57,300,000 shares of its common stock, which represents a
controlling interest in Medical Care Technologies, Inc. As a result of
this transaction, there was a change of control.
|
|
|
|
Based on the change in ownership, the assets were
recorded based on historical basis and totaled $471,128. Pursuant to the
agreement, on February 1, 2010, the Company cancelled 57,300,000 shares of
common stock from the former President of the Company and issued these
shares to Great Union.
|
F-4
Medical Care Technologies Inc.
|
(A Development Stage Company)
|
Notes to the Consolidated Financial Statements
|
(unaudited)
|
2.
|
Asset Acquisition Agreement (continued)
|
The assets acquired are stated at cost
and has the following remaining useful lives. Amortization is calculated using
straight-line method over the remaining lives.
Computer hardware
|
1 year
|
Equipment
|
2 year
|
Computer software and database
|
1 year
|
Amortization and depreciation expense
totaled $230,564 and $nil for the six months ended June 30, 2010 and 2009,
respectively.
3.
|
Related Party Transactions
|
|
|
|
|
During the six months ended June 30, 2010, the Company
recognized $30,000 of management fees. At June 30, 2010, the Company is
indebted to the President of the Company for $33,011, representing $30,000
of management fees owed and $3,011 of expenditures paid on behalf of the
Company this amount is unsecured, bears no interest and is due on demand.
The Company is also indebted to a former director for $1,994 representing
expenditures paid on behalf of the Company.
|
|
|
|
4.
|
Loans payable
|
|
|
|
|
a)
|
On August 8, 2009, the Company received $5,636
(Cdn$6,000) and entered into a promissory note agreement. Under the terms
of the note, the principal of the loan is unsecured and bears no interest
if repaid by April 1, 2010. The Company failed to make the principal
repayment on April 1, 2010. The note currently bears interest of 12% per
annum and is repayable on April 1, 2011. In the event of default, the
principal and all accrued interest shall be due and payable
thereon.
|
|
|
|
|
b)
|
On August 9, 2009, the Company borrowed $22,000 and
entered into a promissory note agreement. Under the terms of the note, the
principal of the loan is unsecured and bears no interest if repaid by
April 1, 2010. The Company failed to make the principal repayment on April
1, 2010. The note currently bears interest of 12% per annum and is
repayable on April 1, 2011. In the event of default, the principal and all
accrued interest shall be due and payable thereon.
|
|
|
|
|
c)
|
On August 9, 2009, the Company borrowed $28,740 and
entered into a promissory note. Under the terms of the note, the principal
of the loan is unsecured and bears no interest if repaid by April 1, 2010.
The Company failed to make the principal repayment on April 1, 2010. The
note currently bears interest of 12% per annum and is repayable on April
1, 2011. In the event of default, the principal and all accrued interest
shall be due and payable thereon.
|
|
|
|
|
d)
|
On November 18, 2009, the Company borrowed $14,000
pursuant to a promissory note. Under the terms of the note, the principal
of the loan is unsecured and bears no interest if repaid by April 1, 2010.
The Company failed to make the principal repayment on April 1, 2010. The
note currently bears interest of 12% per annum and is repayable on April
1, 2011. In the event of default, the principal and all accrued interest
shall be due and payable thereon.
|
|
|
|
|
e)
|
On March 30, 2010 the Company borrowed $10,341 pursuant
to a promissory note. Under the terms of the note, the principal of the
loan is unsecured and bears no interest if repaid by April 1, 2010. The
Company failed to make the principal repayment on April 1, 2010. The note
currently bears interest of 12% per annum and is repayable on April 1,
2011. In the event of default, the principal and all accrued interest
shall be due and payable thereon.
|
|
|
|
5.
|
Common and Preferred Stock
|
|
|
|
|
a)
|
The preferred stock may be divided into and issued in
series by the Board of Directors. The Board is authorized to fix and
determine the designations, rights, qualifications, preferences,
limitations and terms, within legal limitations. As of June 30, 2010 and
December 31, 2009, there was no preferred stock issued and
outstanding.
|
|
|
|
|
b)
|
On February 1, 2010, 57,300,000 shares of common stock
were cancelled and returned to treasury by the former President of the
Company for $nil consideration.
|
|
|
|
|
c)
|
On February 1, 2010, 57,300,000 shares of common stock
with a fair value of $471,128 were issued pursuant to the Asset
Acquisition Agreement with Great Union Corporation described in Note
2.
|
F-5
|
d)
|
On January 15, 2010, the Company accepted subscriptions
for 500,000 units at $0.20 per unit for cash proceeds of $100,000. Each
unit consists of one share of common stock of the Company and one common
share purchase warrant exercisable at $0.15 per share for a period of 36
months. The Company issued the shares on February 1,
2010.
|
F-6
ITEM 2.
|
MANAGEMENTS DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
|
Forward-Looking Statements
This quarterly report includes a
number of forward-looking statements that reflect our current views with respect
to future events and financial performance. Forward-looking statements are often
identified by words like: believe, expect, estimate, anticipate, intend, project
and similar expressions, or words which, by their nature, refer to future
events. You should not place undue certainty on these forward-looking
statements, which apply only as of the date of this report. These
forward-looking statements are subject to certain risks and uncertainties that
could cause actual results to differ materially from historical results or our
predictions.
We are a start-up, development
stage-corporation and have not yet generated or realized any revenues from our
business activities. We incurred a loss of $167,997 for the three months ended
June 30, 2010, a loss of $334,128 for the six months ended June 30, 2010 and had
an accumulated deficit of $512,534 since inception. The Companys ability to
continue as a going concern is uncertain. While management of the Company
believes that the Company will be successful in its current and planned
operating activities, there can be no assurance that the Company will be
successful in the achievement of opening and operating private pediatric
clinics, sale and implementation of its medical software programs, or sales of
its products that will generate sufficient revenues to earn a profit and sustain
the operations of the Company. The Company also intends to conduct additional
capital formation activities through the issuance of its common stock and
loans.
The accompanying consolidated
financial statements have been prepared in conformity with accounting principles
generally accepted in the United States of America, which contemplate
continuation of the Company as a going concern. The Company has not established
sufficient sources of revenues to cover its operating costs and expenses. As
such, it has incurred an operating loss since inception. Further, as of June 30,
2010 the cash resources of the Company were insufficient to meet its planned
business objectives. These and other factors raise substantial doubt about the
Companys ability to continue as a going concern. The accompanying consolidated
financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of assets or the amounts
and classification of liabilities that may result from the possible inability of
the Company to continue as a going concern.
We are actively pursuing short term
and long term financing solutions.
Our Business
On January 9, 2010, we signed an
Asset Acquisition Agreement (Asset Agreement) with Great Union Corporation
(Great Union). In consideration of the issuance of 57,300,000 shares of our
common stock, we acquired Great Unions technologies associated with the
development and maintenance of secure information systems which increase access
to medical resources services, education and wellness, pharmaceutical and
nutraceutical products.
Our mission now is to open and
operate private childrens health clinics throughout China. Concurrent with, and
in addition to the clinics we operate, it is our plan to add to our bottom
revenue line by offering affordable, standardized and secure software
information systems to electronically connect healthcare providers, academic
institutions, pharmaceutical and nutraceutical companies, alternative health
companies and individual consumers with healthcare information, products and
services in China. Initially, we aim to generate e-management revenues and
nutraceutical and pharmaceutical product distribution revenues.
We are a Chinese medical
technology company engaged principally in the business of i) opening and
operating private healthcare services to children in China; ii) developing and
maintaining online secure medical information systems used by hospitals and
other healthcare institutions and; iii) selling pharmaceutical, nutraceutical
and herbal products online and in our proposed private healthcare clinics.
Our current operations consist of
three business segments: Childrens Medical Clinics, Medical Management Software
Systems, and Pharmaceutical and Nutraceutical Products.
3
Private Pediatric Clinics
The company plans to seize the
opportunities available for businesses that provide medical type services in
China by opening and operating private pediatric clinics and mainly locating
them in economically developing and/ developed provinces and urban areas.
Medical Management Software Systems
Modern technology has made it
possible to gather and present health care information economically and
efficiently and we have positioned ourselves to lead the effort to marry
technology and health care information dissemination through two software
information systems we have developed. Our technology will allow the user to
register, monitor, test, interact and manage health records in a seamless
fashion. Our software delivery information systems platforms are - Med-Suite
Professional Practice Management and Tele-Health Suite. The primary customers
served by our software systems are hospitals and clinics; physicians office
practices; pharmaceutical companies and; other healthcare providers. We also
plan to install the software systems in our pediatric clinics.
Pharmaceutical and Nutraceutical Products
It is our strategy to develop or
source and sell high-quality pharmaceutical and nutraceutical products and a
wide variety of other merchandise, including over-the-counter medicines, herbal
products, personal care products, family care products in our planned pediatric
clinics, through our online store website, retail pharmacies and through
established sales and distribution channels in China. We will also offer private
label products, which we believe will distinguish us from our key competitors.
Further, our target customers in this segment are retail pharmacies,
pharmaceutical companies; hospitals; physicians office practices and; the
general public.
Limited Operating History and Need for Additional
Capital
There is no historical financial
information about us upon which to base an evaluation of our performance. We
have just begun our development operations and have not yet generated revenues
from our activities. In January 2010, we signed the Asset Acquisition Agreement
with Great Union and appointed new Board members to carry forth the Companys
operations according to its business plan. Opening and operating private
childrens health clinics, e-management online healthcare services, and selling
and distribution of our pharmaceutical and nutraceutical products are all
potential revenue streams currently being developed by us. Although we expect to
generate revenues from our business activities, there is no guarantee we will be
successful. Our business is subject to risks inherent in the establishment of a
new business enterprise, including limited capital resources and possible delays
in obtaining licenses to operate health services in China. Because we have no
operating history we cannot reliably forecast our future operations.
We have utilized funds obtained
from our January 13, 2010 private placement for corporate organizational
purposes, license payments and; software developmental costs.
In the short term, we require
additional funding for legal and professional fees, continued software
development costs, license fees, market feasibility research studies, accounts
payables and general operating expenses.
In the long term, our anticipated
revenue streams over the next three years are expected to come from operating
childrens clinics, our e-management online healthcare market, pharmaceutical
and nutraceutical supply market. We plan to develop in each of our business
segments new products and services that provide increased benefits to customers.
Our ability to obtain long-term growth will depend on a number of factors,
including our ability to expand our business (including geographical expansion),
source new products with higher gross profit margins, and obtain operating
efficiency and organizational effectiveness.
To become profitable and
competitive, we must be successful in obtaining license approvals from Chinese
government health authorities in order to be able to open and operate private
pediatric clinics throughout China and to generate substantial revenues and
profits.
4
We have no assurance that
financing will be available to us on satisfactory terms. If financing is not
available on satisfactory terms, we may be unable to continue, develop or expand
our activities. Equity financing could result in additional dilution to existing
shareholders.
Results of Operations
As of June 30, 2010, our total
assets were $287,249 and our total liabilities were $177,155. Total assets
increased from December 31, 2009 by $286,774 due to an increase in prepaid
expenses of $45,500 ($45,500 in 2010 and $-0- in 2009); property and equipment
of $30,000 ($30,000 in 2010 and $-0- in 2009) and; an increase in intangible
assets of $210,564 ($210,564 in 2010 and $-0- in 2009). Total liabilities
increased by $49,774. This is mainly due to an increase in accounts payable and
accrued liabilities of $30,231 ($61,433 in 2010 and $31,202 in 2009) and; an
increase in loans payable of $66,717 ($80,717 in 2010 and $14,000 in 2009).
Net Loss.
We incurred a
net loss of $167,997 for the quarter ended June 30, 2010, compared to a net loss
of $25,187 for the quarter ended June 30, 2009. This was mainly due to an
increase of $115,282 in depreciation and amortization expense in the quarter
ended June 30, 2010 on the medical technology acquired in the Asset Acquisition
Agreement with Great Union Corporation. Also, general and administrative
expenses increased by $21,890 in which, for the quarter ended June 30, 2010 was
$38,077 and for the quarter ended June 30, 2009 was $16,187. This increase was
associated with legal and accounting costs pursuant to the acquisition
agreement.
We incurred a net loss of
$334,128 for the six months ended June 30, 2010, compared to a net loss of
$39,930 for the six months ended June 30, 2009. This was mainly due to an
increase of $230,564 in depreciation and amortization expense in the six months
ended June 30, 2010 on the medical technology acquired in the Asset Acquisition
Agreement with Great Union Corporation. Also, general and administrative
expenses increased by $42,687 in which, for the six months ended June 30, 2010
was $73,689 and for the six months ended June 30, 2009 was $31,002. This
increase was associated with legal and accounting costs pursuant to the
acquisition agreement.
From February 27, 2007 (inception
date) to June 30, 2010 we incurred a net loss of $512,534 and had a working
capital deficiency of $130,470.
Our ability to achieve profitable
operations depends on developing revenue through the operation of private
pediatric clinics throughout China. Our expectations are that we will not begin
to show profitable operating results until Year 2 to Year 4.
Liquidity and Capital Resources
The accompanying financial
statements have been prepared on a going concern basis, which implies the
Company will continue to realize its assets and discharge its liabilities in the
normal course of business. We have not generated any revenues and we do not
anticipate to generate any revenues until i) we begin implementing our medical
management software systems and devices in hospitals and clinics; ii) sourcing,
marketing and selling pharmaceutical and nutraceutical products to healthcare
providers and the general public and; iii) opening and serving patients in our
pediatric clinics. Accordingly, we must raise cash from private investors,
through equity financings or by developing strategic alliances with other
leading, world class players in the health industry. We are actively pursuing
financing options to carry out our business operations. We have used the monies
raised in our January 13, 2010 private placement for license fees and corporate
purposes. Our success or failure will be determined by creating alliances with
healthcare providers who need our medical technology, selling a large volume or
our products and opening a number of private pediatric clinics throughout
China.
On January 13, 2010, we completed
a non-brokered private placement of 500,000 units at a price of US$0.20 per unit
for total proceeds of US$100,000. Each unit purchased is comprised of one share
of common stock and one Series A Warrant. Each Series A Warrant is
non-transferable and is convertible into one share of common stock upon payment
of $0.15 per Series A Warrant, exercisable for a period of twenty four (24)
months. The units were sold pursuant to the exemption from registration
contained in Regulation S of the Securities Act of 1933 in that the transaction
took place outside the United States of America and the purchaser was a non-US
person as defined in Regulation S. The securities that comprise the units are
restricted securities as that term is defined in Rule 144 of the Securities
Act of 1933.
5
Cash on hand as of August 13,
2010 is $1,185. Net cash used for operating activities was $118,833 for the
quarter ended June 30, 2010 compared to operating activities of $11,598 for the
quarter ended June 30, 2009. Operating expenses for the quarter ended June 30,
2010 included i) $230,564 in depreciation and amortization expenses; ii) paid
down prepaid expenses of $45,500 and; iii) $30,231 in accounts payable and
accrued liabilities We anticipate that overhead costs will increase in the near
term as we increase our operational activities.
Cash flows provided by financing
activities accounted for $119,543 for the six months ended June 30, 2010
compared to financing activities of $1,994 for the six months ended June 30,
2009. For the six months ended June 30, 2010, financing activities included an
issuance of common stock for cash of $100,000; an increase in loans payable of
$9,977 and an increase in related party loans of $9,566.
Limited Capital
We are currently in discussions
with investors to raise the funds necessary to carry out our operational plans
and continue our business activities. At the present time, we have no
commitments for any additional financing, and there can be no assurance that, if
needed, additional capital will be available to use on commercially acceptable
terms or at all. Our failure to raise capital as needed would significantly
restrict our growth and hinder our ability to compete. We may need to curtail
expenses, and forgo business opportunities. Additional equity financings are
likely to be dilutive to holders of our common stock and debt financing, if
available, may involve significant payment obligations and covenants that
restrict how we operate our business. If we are unable to secure funds to
finance our operations, we may examine other possibilities, including, but not
limited to, mergers or acquisitions.
Management believes the ability
of the Company to continue as a going concern, earn revenues and achieve
profitability is highly dependent on a number of factors including our ability
to obtain sufficient financing to prepare a market analysis for submission to
the appropriate state authorities in China in order to procure the necessary
licensing approvals of establishing childrens health clinics. We have already
completed a White Paper which outlines our vision for operating childrens
health clinics in China. To the end of our fiscal year, operations are dependent
on securing financing of approximately $500,000 to $3,500,000.
Off-Balance Sheet Arrangements
We have not entered into any
transactions with unconsolidated entities in which we have financial guarantees,
subordinated retained interests, derivative instruments or other contingent
arrangements that expose us to material continuing risks, contingent liabilities
or any other obligations under a variable interest in an unconsolidated entity
that provides us with financing, liquidity, market risk or credit risk
support.
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.
|
We are a smaller reporting
company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are
not required to provide the information under this item.
ITEM 4.
|
CONTROLS AND PROCEDURES.
|
Under the supervision and with
the participation of our management, including the Principal Executive Officer
and Principal Financial Officer, we have evaluated the effectiveness of our
disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as
of the end of the period covered by this report. Based on that evaluation, the
Principal Executive Officer and Principal Financial Officer have concluded that
these disclosure controls and procedures are not effective. In making this
assessment, it used the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO) in
Internal
Control-Integrated Framework
. Based on our assessment, we believe that, as
of June 30, 2010, our internal control over financial reporting was not
effective based on those criteria due to a lack of segregation of duties, a lack
of qualified accounting staff and an overreliance on consultants in our
accounting and financial reporting process. A material weakness is a deficiency,
or a combination of control deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of our annual or
interim financial statements will not be prevented or detected on a timely
basis. Notwithstanding, at this time management has decided that considering the
abilities of the persons involved and the control procedures now in place, the
risks associated with such lack of segregation are low and the potential
benefits of adding employees to further segregate duties do not justify the
substantial expenses associated with such increases. Management will
periodically reevaluate this situation.
6
There were no changes in our
internal control over financial reporting during the quarter ended June 30, 2010
that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.
|
LEGAL PROCEEDINGS.
|
We know of no material, existing
or pending legal proceedings against our company, nor are we involved as a
plaintiff in any material proceeding or pending litigation. There are no
proceedings in which any of our directors, officers or affiliates, or any
registered or beneficial shareholder, is an adverse party or has a material
interest adverse to our interest.
We are a smaller reporting
company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are
not required to provide the information under this item.
ITEM 2.
|
UNREGISTERED SALES OF EQUITY SECURITIES AND
USE OF PROCEEDS.
|
None.
ITEM 3.
|
DEFAULTS UPON SENIOR SECURITIES.
|
None.
ITEM 4.
|
[REMOVED AND RESERVED].
|
|
|
ITEM 5.
|
OTHER EVENTS.
|
None.
The following documents are included
herein:
7
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
|
MEDICAL CARE TECHNOLOGIES INC.
|
|
|
|
|
|
|
Dated: August 13, 2010
|
BY:
|
/s/
Ning C. Wu
|
|
|
Ning C. Wu,
|
|
|
President, Principal Executive Officer,
|
|
|
Principal Financial Officer, Principal
|
|
|
Accounting Officer and a member of the
|
|
|
Board of Directors.
|
8
EXHIBIT INDEX
9
Medical Care Technologies (PK) (USOTC:MDCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medical Care Technologies (PK) (USOTC:MDCE)
Historical Stock Chart
From Jul 2023 to Jul 2024